EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in the structural modification of Alzheimer’s disease drug – Huperzine A

Xiaoxin Zhu, Jin-Bu Xu, Feng Gao, Lin-Xi Wan

Bioorganic Chemistry · 2025-01 · 154 · 108012

DOI: 10.1016/j.bioorg.2024.108012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025-01. Verfasst von Xiaoxin Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Alkaloids, Sesquiterpenes, Cholinesterase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Huperzine A is an alkaloid featuring a bicyclo [3.3.1] nonane scaffold with an integrated piperidine ring, which was firstly isolated from Huperzia selago in 1960. As a reversible acetylcholinesterase inhibitor, it was clinically approved in China for treatment of Alzheimer's disease in 1996. Although huperzine A shows therapeutic potential, it is often associated with adverse events, such as dizziness, nausea, and digestive disorders. To enhance the efficacy and therapeutic index of huperzine A, many structural modification efforts have been undertaken. This review comprehensively summarizes the structural modification investigations on huperzine A conducted over the past three decades, and the structure-activity relationships are also discussed. The insights from this review are expected to inspire more effective modification strategies in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAlkaloidsSesquiterpenesCholinesterase InhibitorsHumansStructure-Activity RelationshipMolecular StructureAcetylcholinesteraseAnimalsHuperzia

Stichwörter der Autor:innen

Acetylcholinesterase inhibitionAlzheimer’s diseaseHuperzine AStructure modificationStructure-activity relationships

Substanzen

huperzine AAlkaloidsSesquiterpenesCholinesterase InhibitorsAcetylcholinesterase

Autor:innen und Institutionen

  • Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; Key Laboratory of Advanced Technologies of Mat…
  • Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China; Yibin Institute of Southwest Jiaotong Universi…
  • Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. Electronic address: wanlx@scu.edu.cn.

Förderung

  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhu, X., Xu, J. B., Gao, F., & Wan, L. X. (2025). Advances in the structural modification of Alzheimer’s disease drug – Huperzine A. Bioorganic Chemistry, 154, 108012. https://doi.org/10.1016/j.bioorg.2024.108012

Vancouver

Zhu X, Xu JB, Gao F, Wan LX. Advances in the structural modification of Alzheimer’s disease drug – Huperzine A. Bioorganic Chemistry. 2025;154:108012. doi:10.1016/j.bioorg.2024.108012

BibTeX
@article{Zhu2025,
  author = {Zhu, Xiaoxin and Xu, Jin-Bu and Gao, Feng and Wan, Lin-Xi},
  title = {Advances in the structural modification of Alzheimer’s disease drug – Huperzine A},
  journal = {Bioorganic Chemistry},
  year = {2025},
  volume = {154},
  pages = {108012},
  doi = {10.1016/j.bioorg.2024.108012}
}
Kostenlos starten →